Key result
Artesunate strongly inhibited collagen-induced human platelet aggregation with an IC50 of 106.41 µM through the regulation of PI3K/Akt and MAPK pathways.
Why the study?
Excessive platelet activation and aggregation cause cardiovascular disease, but the effect and mechanism of artesunate on collagen-induced platelet activation and aggregation have not been elucidated.
Does artesunate inhibit collagen-induced aggregation in human platelets?
Does artesunate inhibit collagen-induced aggregation in human platelets?
Answers are grounded in this paper and cite their sources.
Artesunate inhibits collagen-induced human platelet aggregation by suppressing PI3K/Akt and MAPK signaling pathways, suggesting potential as an antithrombotic agent.
Excessive activation and aggregation of platelets is a major cause of cardiovascular disease. Therefore, inhibition of platelet activation and aggregation is considered an attractive therapeutic target in preventing and treating cardiovascular diseases. In particular, strong platelet activation and aggregation by collagen secreted from the vascular endothelium are characteristic of vascular diseases. Artesunate is a compound extracted from the plant roots of Artemisia or Scopolia species, and has been reported to be effective in anticancer and Alzheimer's disease fields. However, the effect and mechanism of artesunate on collagen-induced platelet activation and aggregation have not been elucidated. In this study, the effect of artesunate on collageninduced human platelet aggregation was confirmed and the mechanism of action of artesunate was clarified. Artesunate inhibited the phosphorylation of PI3K/Akt and Mitogen-activated protein kinases, which are phosphoproteins that are known to act in the signal transduction process when platelets are activated. In addition, artesunate decreased TXA 2 production and decreased granule secretion in platelets such as ATP and serotonin release.
No takes yet. Share an insight, caveat, or question.
Dong‐Ha Lee (2022) studied Platelet aggregation. Artesunate vs. Collagen alone (vehicle control) was evaluated on Collagen-induced platelet aggregation (IC50 106.41 µM, p=<0.001). Artesunate strongly inhibited collagen-induced human platelet aggregation with an IC50 of 106.41 µM through the regulation of PI3K/Akt and MAPK pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: